EMG and SSEP Device (EPAD® 2.0) for Intraoperative Monitoring of Patient Undergoing Spinal Nerve Spine Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03848377|
Recruitment Status : Not yet recruiting
First Posted : February 20, 2019
Last Update Posted : March 6, 2019
|First Submitted Date||February 19, 2019|
|First Posted Date||February 20, 2019|
|Last Update Posted Date||March 6, 2019|
|Estimated Study Start Date||July 2019|
|Estimated Primary Completion Date||June 2021 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures
||The feasibility of using EPAD 2.0 automated device to successfully monitor the patients in spine surgery. [ Time Frame: Intraoperative ]
The feasibility is determined by the percentage of patients being successfully monitored in spine surgery using the EPAD 2.0 automated device (i.e. [number of patients being successfully monitored/ total number of patients being recruited]*100).
|Original Primary Outcome Measures||Same as current|
|Change History||Complete list of historical versions of study NCT03848377 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures||Not Provided|
|Original Secondary Outcome Measures||Not Provided|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title||EMG and SSEP Device (EPAD® 2.0) for Intraoperative Monitoring of Patient Undergoing Spinal Nerve Spine Surgery|
|Official Title||A Feasibility Study of a Novel Combined Automated EMG and SSEP Device (EPAD® 2.0) for Intraoperative Monitoring of Spinal Nerve Roots and Spinal Cord Function During Spine Surgery|
|Brief Summary||In patients undergoing spine surgery, spinal nerve roots and spinal cord are vulnerable to surgical insults especially for instrumentation and may lead to long term sequelae. The incidence of clinical peripheral neuropathy after cervical spine surgery has been reported up to 30%. Intraoperatively, spinal cord and nerves function can be monitored using electromyography (EMG) and somatosensory evoked potentials (SSEP) and thereby, intervention can be made to potentially reduce the incidence of adverse neurological sequelae. However, conventional EMG and SSEP monitoring requires presence of a trained EP technician, use of needle electrodes and currently bulky EP equipment and is thus not practical for routine clinical usage. In this study, the invesitgators will assess the clinical feasibility of using a novel miniaturized and automated EMG/SSEP device (EPAD® 2.0) in spine surgical patients.|
Purpose of Research: This study is a pilot study designed to assess the ability of a novel automated EMG/SSEP device (EPAD® 2.0) to detect intraoperative spinal nerve roots injury in patients undergoing spine procedures. The specific aims are:
Hypothesis: the novel automated EPAD® 2.0 EMG/SSEP device is easy to use and apply in spine surgery patients
BACKGROUND Surgical injuries to the spinal nerve roots or spinal cords are not infrequent in spine surgery and the consequence can be devastating. Injured patients might present with radiculopathy, motor weakness, spinal cord compression, and postoperative neuropathic pain. In cervical spine surgery, cervical nerve roots injuries especially fifth cervical (C5) nerve root are not uncommon complications, potentially resulting in upper extremity paralysis. The incidence of C5 nerve root injury ranged to as high as 30%. The other spinal nerve roots (C6-8) can suffer from the same surgical injuries during the procedure but with much lower reported incidence than C5. Spinal nerve injuries typically occur during decompression for cervical myelopathy in both anterior and posterior approaches. In lumbosacral spine surgery, a recent review of the neurological injury found a pooled incidence of 5.7% (56 of 2783 patients; range: 0.46-24%), in which pedicle malposition accounted for one-fifth of the injuries.
A multimodality monitoring such as SSEP and EMG can be used in spine surgery to allow comprehensive monitoring of the spinal cord and nerve roots function and an attempt to reduce the risks of surgical injuries. Although the idea of closely monitoring of spinal cord and nerve roots function during high-risk cervical spine instrumentation procedure is appealing, the utilization of intraoperative neurophysiological monitoring is limited. One reason is the current requirements for a trained technician and for electrode placement and observation of monitoring SSSEP signals, the requirement for the use of needle electrodes for SSEP monitoring and specific training for a neurophysiologist in the interpretation of SSEP signals.
In attempt to resolve this problem, the investigators has been involved in developing an automated SSEP device (EPAD®, SafeOp Surgical, Hunt Valley, MD; FDA approved). The automated EPAD1.0 SSEP device the investigators are currently utilizing is miniaturized and incorporates a proprietary technology utilizing non-invasive electrode patches (rather than needle electrodes) and is based on an automated algorithm derived from real-time SSEP monitoring of over 100,000 surgical procedures. The investigators was the first to evaluate the clinical utility of this automated SSEP device in cardiac surgical and total shoulder arthroplasty patients. These pilot studies found that automated SSEP monitoring can be performed readily in a busy cardiac operating room, as well as in orthopedic surgery. The raw signal quality is reliable and comparable to the conventional SSEP machine. These results indicate that this device can eliminate the practical challenges of performing SSEP monitoring and confirmed its feasibility for routine use. The initial experience has enabled further development that has incorporated software updates based on off-line data-reiteration. This has also allowed progressive refinement of the automated analysis algorithm based on this recently acquired intraoperative SSEP data to progressively optimize the software for improved signal acquisition, enhanced artifact rejection and electrocautery suppression.
METHOD Study Design This will be a prospective cohort study aiming in assessing the ability of a novel automated EMG/SSEP device (EPAD® 2.0) to detect intraoperative spinal nerve root injury in patients undergoing spine procedures. All protocol procedures will be undertaken; however, as this is the first clinical trial of EPAD® 2.0, the initial series of up to 30 patients will be used for feasibility anticipating some possible minor software revisions and minor equipment modifications. Additionally, data obtained from this initial series of patients may be utilized to iteratively refine the data collection and analysis algorithms.
Standard Procedure After obtaining preoperative written consent, a brief neurological exam will be conducted. As is conventional, anesthesia will be induced using opioid/propofol and will be maintained with halogenated anesthetic agents and supplemented with an infusion of remifentanil at 0.01-0.2 mcg/kg/min or sufentanil at 0.15 to 0.5g/kg/hr. Muscle relaxants will only be given for intubation and no second dose will be given to enable EMG monitoring. After anesthesia induction with airway and vascular access secured, the patient will be positioned for the surgery. There is no change in routine (or standard) of care except the investigators will attach the EPAD 2.0 device to the patients. After the surgery, the patient will be extubated and transferred to PACU. In all patients, a complete neurological exam will be performed in PACU.
For SSEP monitoring, surface adhesive electrodes will be used for both stimulation and recording. Stimulating electrodes will be placed for stimulation of the dermatome that is at risk of injury (e.g. C5), median nerve or posterior tibal nerve. Recording surface electrodes will be placed on the cervical spine at the C2 level (C2), and the reference electrode was placed on the forehead. The pre-set stimulation frequency in the EPAD device is 4.7 Hz with a 300- microsecond pulse set at 50 to 70 mA and the signal averaging set at 300 cycles. After an automatic impedance check, the baseline subcortical SSEP will be established at the beginning of each case, and the amplitude and latency of the waveforms will be measured. The EPAD device automatically established the baselines.
For EMG monitoring, 6 Surface electrodes will be attached to the same muscle groups of the conventional intraoperative neurophysiological monitoring machine. The underlying skin will be prepared with 3M EKG skin abrasive tape (3M red dot 2236) to reduce the skin impedance. In each case, the Compound Muscle Action Potentials (CMAPs) of each muscle group will be monitored. The EMG monitoring can provide three main functions in spine surgery, which includes free-run EMG for detecting mechanical irritation to nerve root, triggered EMG for nerve root identification and pedicle screw placement assessment. All three EMG functions will be evaluated in this study.
Short Summary of Study Protocol:
|Study Design||Observational Model: Cohort
Time Perspective: Prospective
|Target Follow-Up Duration||Not Provided|
|Sampling Method||Probability Sample|
|Study Population||Study Participants: 30 patients who are scheduled to have spine surgery in LHSC.|
|Study Groups/Cohorts||Automated EMG/SSEP monitored
In this study, all patients will be monitored for SSEP and EMG. For SSEP monitoring, surface adhesive electrodes will be used for both stimulation and recording. After an automatic impedance check, the baseline subcortical SSEP will be established at the beginning of each case, and the amplitude and latency of the waveforms will be measured. For EMG monitoring, 6 Surface electrodes will be attached to the same muscle groups of the conventional intraoperative neurophysiological monitoring machine. In each case, the Compound Muscle Action Potentials (CMAPs) of each muscle group will be monitored.
As this is an observational study, no intervention is planned.
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status||Not yet recruiting|
|Original Estimated Enrollment||Same as current|
|Estimated Study Completion Date||June 2021|
|Estimated Primary Completion Date||June 2021 (Final data collection date for primary outcome measure)|
|Ages||18 Years and older (Adult, Older Adult)|
|Accepts Healthy Volunteers||No|
|Listed Location Countries||Not Provided|
|Removed Location Countries|
|Other Study ID Numbers||112933|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||
|IPD Sharing Statement||Not Provided|
|Responsible Party||Jason Chui, Lawson Health Research Institute|
|Study Sponsor||Lawson Health Research Institute|
|PRS Account||Lawson Health Research Institute|
|Verification Date||March 2019|